Engineered Dendritic Cell Vaccines for Multiple Myeloma

Sex: All

Ages: 18 Years – 80 Years

Healthy volunteers: No

Phase: PHASE1

Enrollment: 10

Sponsor: Shenzhen Geno-Immune Medical Institute

Summary

The purpose of this study is to determine the feasibility, safety, and efficacy of dendritic cell (DC) vaccines in the treatment of multiple myeloma (MM) or plasmacytoma based on immune-modified DC vaccines (DCvac). This approach is aimed to achieve prolonged maintenance of remission in multiple myeloma or plasmacytoma patients.

Eligibility Criteria

Inclusion Criteria: * Male and female subjects with multiple myeloma or plasmacytoma * Very good partial or complete remission (CR) after prior combination therapies. * Expected survival \> 12 weeks * Adequate venous access for blood withdrawal or apheresis, and no other contraindications for blood withdrawal * Voluntary informed consent is given with willingness to continue follow up Exclusion Criteria: * Pregnant or lactating women * Uncontrolled active infection * HIV or active hepatitis B or hepatitis C infection * Concurrent use of systemic steroids; the use of inhaled steroids is not exclusionary

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT06435910). StuddyBuddy aggregates publicly available trial information.